Actively Recruiting
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Led by Hospital Universitario Dr. Jose E. Gonzalez · Updated on 2026-04-01
10
Participants Needed
1
Research Sites
76 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
CONDITIONS
Official Title
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have relapsed or refractory diffuse large B-cell lymphoma and have had at least one prior treatment
- Eligible for autologous stem cell transplantation
- ECOG performance status between 0 and 2
- Women of childbearing potential agree to use contraception
- Meet Lugano criteria for disease activity
- Voluntarily agree to participate in the study
You will not qualify if you...
- Have an active bacterial, viral, or fungal infection
- Have previously received autologous or allogeneic stem cell transplantation
- Have other active cancers
- Have end-stage organ failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, Mexico, 64640
Actively Recruiting
Research Team
P
Perla R Colunga-Pedraza, MD
CONTACT
N
Natalia Huergo-Treviño, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here